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a  b  s  t  r  a  c  t
To  evaluate  the  efﬁcacy  of  a new  agent,  palonosetron,  in  Hodgkin  Lymphoma  patients  treated  with  ABVD
regimen.  Complete  response  during  the  overall  phase  of  the  ﬁrst  ABVD  cycle,  was the  primary  endpoint.
Secondary  end  points  were:  emesis-free  patients  and  use  of  rescue  medication  during  the acute  and
overall  phases.  From  January  2008  to February  2009  36  patients  were  enrolled.  The  primary  endpointvailable online 14 July 2011
eywords:
hemotherapy-induced nausea and
omiting (CINV)
BVD regimen
odgkin Lymphoma
(CR  0–120  h)  was  achieved  by 55.6%  patients.  In conclusion  our  study  demonstrated  that  a  single dose  of
palonosetron  plus a single  dose  of  dexamethasone  was  effective  in preventing  CINV  in  patients  treated
with  ABVD  regimen.
© 2011 Elsevier Ltd. Open access under CC BY-NC-ND license. . Introduction
Chemotherapy-induced nausea and vomiting (CINV) are among
he most common distressing symptoms experienced by cancer
atients [1].  Failure of CINV control could lead to low patient adher-
nce to cancer treatment, development of anticipatory vomiting
nd deterioration in quality of life [1].
Patient and chemotherapy risk factors may  contribute to an
ncreased probability of experiencing CINV [2].  Young age, female
ender, previous experience of nausea and vomiting in previous
hemotherapy cycles, low or no alcohol assumption, history of
weating and dizziness are patient-speciﬁc risk factors for CINV.
ype, amount and combination of drugs are chemotherapy-speciﬁc
isk factors [1].  Antiemetic guidelines [2,3] have categorized the
metic risk of antineoplastic agents as high (>90% emetic risk),
oderate (from 30% to 90%), low (from 10% to 30%) and minimal
<10%) [3].
The ABVD regimen (adriamycin, bleomycin, vinblastine and
acarbazine) is considered the standard of care for ﬁrst-line treat-
ent of Hodgkin Lymphoma [4].  Among the components of the
BVD regimen, dacarbazine is the most emetogenic drug, accord-
ng to Hesketh classiﬁcation [5],  while adriamycin is classiﬁed as
oderately emetogenic chemotherapy (MEC) and bleomycin and
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Open access under CC BY-NC-ND license. vinblastine have a negligible emetic risk. Patients treated with
ABVD regimen have a high risk of CINV due to antineoplastic agents
and also to additional factors such as young age [3–5] and the efﬁ-
cacy of antiemetic drugs has never been assessed in a prospective
clinical trial in this setting. In published clinical trials assessing the
activity of ABVD regimen the incidence of CINV of grade 3 and 4
(more than 6 daily episodes of vomiting, anorexia and need of tube
feeding) ranged from 5% to 26% [6–8]. In this setting, successful
control of nausea and vomiting could help to improve quality of
life and ability to perform daily activities and to ensure completion
of malignancy treatment.
In the 1990s, the introduction of ﬁrst generation serotonin
receptor antagonists (5-HT3RAs) and the addition of dexametha-
sone improved the management of CINV, respectively [9–13].
However, the control of delayed CINV (the risk is extended up to
120 h post chemotherapy) remained unsatisfactory and the use of
multiple doses of 5-HT3RA beyond 24 h after chemotherapy for
prevention of delayed emesis was  ineffective [14]. Palonosetron, a
second generation 5-HT3RA [15], has demonstrated superiority for
the prevention of emesis in the delayed phase in MEC randomised
trials when compared with ﬁrst generation 5-HT3RAs [16–20].
Additionally, palonosetron has been shown to signiﬁcantly reduce
the severity of nausea to a greater extent than other 5-HT3RAs
[16,17,21].  The greater clinical efﬁcacy of palonosetron compared
with earlier 5-HT3RAs could be partly due to its potent binding
afﬁnity [22], long half-life [23] and unique chemical structure [24].
Recent research [25,26] has shown that palonosetron, in contrast to
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Fig. 1. Proﬁle of emesis control during the 2 evaluated ABVD administrations.
Emesis: patients experienced emesis, emesis-rree: patients did not experience any
common adverse events were transient constipation, treated with
stimulant laxative (such as senna) and headache as expected.
Table 1
Patient characteristics. a1–2 Glasses of wine and badministration on day 1 and on
day  15 of the ﬁrst ABVD cycle.
Demographics N = 36
Age (years)
Median (range) 33.5 (19–65)
Gender, n (%)
Male 23 (63.9)
Female 13 (36.1)
PS  (ECOG), n (%)
0 35 (97.2)
1  1 (2.8)
Alcohol consumption, n (%)
No 24 (66.7)L. Rigacci et al. / Leukemi
ndansetron and granisetron, exhibits allosteric interactions, trig-
ers receptor internalisation and exhibits prolonged inhibition of
eceptor function.
The aim of our study was to assess the efﬁcacy of a single dose
f palonosetron and a single dose of dexamethasone in preventing
INV in patients with Hodgkin Lymphoma receiving ABVD regimen.
. Patients and methods
This was a single centre, prospective, non-comparative study conducted in the
ematology Unit of Careggi Hospital (Florence, Italy) according to Good Clinical
ractice guidelines and Declaration of Helsinki.
.1. Study population
Patients with a histologically conﬁrmed diagnosis of Hodgkin Lymphoma suit-
ble for ABVD (A: adriamycin 25 mg/mq  day 1 and day 15, B: bleomycin 10 U/mq day
 and day 15; V: vinblastine 6 mg/mq  day 1 and day 15; D: dacarbazine 375 mg/mq
ay  1 and day 15) chemotherapy were eligible for the study. Further eligibility cri-
eria  were: age ≥ 18 years, PS 0-1 (ECOG scale), and acceptable hepatic and renal
unction (creatinine <1.5 times the upper limit of normal).
.2. Treatment plan
Chemotherapy-näive patients received a single intravenous (i.v.) bolus of
alonosetron 0.25 mg  plus dexamethasone 8 mg i.v. 30 min  before chemotherapy
dministration. Patients did not receive other scheduled antiemetic treatments fol-
owing chemotherapy administration.
Rescue antiemetic medication (metoclopramide and/or dexamethasone only),
as given at the patient’s request, for the treatment of CINV, in addition to the
dministration of study drugs.
.3. Observation period
Episodes of nausea and vomiting and the use of rescue medication were assessed
rom the administration of antiemetic treatment day 1 throughout day 5 and
rom day 15 throughout day 19 of the ﬁrst cycle. To assess efﬁcacy, patients were
nstructed to record the relevant study information in a diary provided by the inves-
igators. Patients made daily entries in the diary for 5 days after chemotherapy
nitiation to record the number and time of any emetic events, use of rescue medi-
ation, and maximum grade of nausea according to a Likert scale. Patients also made
aily entries in the diary noting any adverse event or use of concomitant medication.
.4. Study endpoints
The primary endpoint of the study was deﬁned as the percentage of patients who
chieved a complete response (CR) during the overall phase of the ﬁrst chemother-
py  administration. CR was deﬁned as no vomiting episodes and no use of rescue
edication, while the overall phase was deﬁned as from 0 h to 120 h after the start
f  chemotherapy (days 1–5).
Secondary endpoints are CR during the acute phase of the ﬁrst administration
nd CR during the acute and overall phases of the second ABVD administration
days 15–19). Other endpoints were the percentage of patients without any emetic
pisodes and any use of rescue medication during the acute (day 1 and day 15) and
oth overall phases (days 1–5; days 15–19) of both ABVD administrations. Nausea
as assessed according to a Likert scale during the overall phase. Treatment safety
as evaluated during the study and all adverse events were recorded and graded
ccording to the common terminology criteria for adverse events (CTCAE) of the
ational Cancer Institute, version 4.0. (http://ctep.cancer.gov/forms/CTCAEv4.pdf).
.5. Statistical analysis
Demographic data and patient characteristics were examined. Descriptive
tatistics were used to analyse the primary and secondary endpoints.
. Results
Between January 2008 and February 2009, 36 chemotherapy-
aive Hodgkin Lymphoma patients were enrolled in the study and
 total of 63 ABVD chemotherapy regimens have been admin-
stered and evaluated for study endpoints. All patients received
BVD regimen as ﬁrst-line treatment. Most of the patients were
oung (median age 33.5 years) and male 23 (63.9%). All patients
eceived study treatment during both administrations of ABVD
day 1 and day 15), but 9 patients did not return the diary atemetic episodes, and *not evaluable: patients did not return the diary or reported
no CINV during the study assessment period.
the second administration. Those patients reported no CINV dur-
ing the second administration, therefore they were considered not
evaluable for the efﬁcacy parameters during the second admin-
istration. 36 patients were evaluable for the ﬁrst administration
while only 27 were evaluable for the second administration of
the ﬁrst ABVD cycle (Fig. 1). Patient characteristics are listed in
Table 1.
3.1. Efﬁcacy results
Complete response during the overall phase was 55.6% (17/36
patients) (Table 2 and Fig. 2). All secondary endpoints are reported
in Table 2. Most of the patients did not experience emesis dur-
ing the overall phase of the ﬁrst (86.1%) and the second (85.2%)
administration of the ﬁrst ABVD cycle. No grade 3 (more that 6 vom-
iting episodes) or grade 4 (life threatening event) vomiting were
detected during both administrations. Due to the nausea experi-
enced (Table 2), 38.9% of patients used rescue medication during
the overall phase of the ﬁrst administration.
Among the 36 evaluated patients, 21 (58.3%) experienced no
episodes of emesis during both administrations (Fig. 1).
Administration of palonosetron was  well tolerated and the mostEvery daya 12 (33.3)
Evaluated administrationb, n (%)
1 (day 1) 36 (100)
2  (day 15) 27 (75)
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Table 2
Efﬁcacy results. Complete response, emesis free and no use of rescue medication
rates during the acute and overall phases. Incidence of nausea is reported according
to  a Likert scale during the overall phase (0–120 h).
Variable Administration
1 (day 1)
Administration
2 (day 15)
Primary endpoint
CR overall % (n/N) 55.6 (17/36)
Secondary endpoints
CR acute 91.7 (33/36) 88.9 (24/27)
CR overall 85.9 (23/27)
Emesis free acute 91.7 (33/36) 85.2 (23/27)
Emesis free overall 86.1 (31/36) 85.2 (23/27)
No use of rescue medication acute 91.7 (33/36) 96.3 (26/27)
No use of rescue medication overall 61.1 (22/36) 88.9 (24/27)
No nausea overall 30.6 (11/36) 25.9 (7/27)
Mild nausea overall 25 (9/36) 25.9 (7/27)
Moderate nausea overall 36.1 (13/36) 40.8 (11/27)
Severe nausea overall 8.3 (3/36) 7.4 (2/27)
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vR: complete response (no vomiting and no use of rescue medication); acute
0–24 h); overall (0–120 h).
. Discussion
This is the ﬁrst trial assessing the efﬁcacy of an antiemetic
rophylaxis in Hodgkin Lymphoma patients receiving the ABVD
egimens. In our study a single antiemetic combination of
alonosetron (0.25 mg)  plus dexamethasone (8 mg), on day 1,
chieved a high control of emesis during the 5-day period of the
rst administration of the ABVD regimen (CR rate of 55.6% and
mesis-free rate of 86.1% during the overall phase). The evalua-
ion of each component of the primary endpoint (vomiting and use
f rescue medication) reported 86.1% of patients with no vomiting
nd 61.1% with no use of rescue medication during the observation
eriod (Fig. 2 and Table 2). In addition, 58.3% of the whole pop-
lation experienced no episodes of vomiting during the ﬁrst two
dministrations of the ﬁrst cycle.
Nausea remains one of the most difﬁcult adverse events to con-
rol, partly due to the subjectivity and difﬁculty of measuring the
ffect of the treatment. In our trial we achieved acceptable con-
rol of nausea with 51.8% of patients without moderate or severe
ausea during the 5 days of observation.
The ABVD regimen has a high emetogenic risk of CINV, due to
he presence of dacarbazine. Before the introduction of antiemetic
rugs, ABVD regimen produced severe nausea and vomiting in
bout 50% of patients [27]. CINV along with fatigue and hair lost
nduced patients to refuse to complete the last planned chemother-
py cycles [27]. After the introduction of ﬁrst generation 5-HT3-RA
ig. 2. Complete response during the acute and overall phases of the ﬁrst
hemotherapy administration, with the evaluation of the separate components: no
omiting and no use of rescue medication.
[
[arch 36 (2012) 182– 185
in ABVD clinical trials [6–8], even if an antiemetic therapy has
been administered, the incidence of vomiting of grades 3 and
4 still ranged from 5% to 26%. To note that authors did not
declare if antiemetic prophylaxis has been conducted according to
antiemetic guidelines [6–8]. In our trial no grade 3 or 4 vomiting
episodes were reported, also if our trial population was younger
and at a higher risk of emesis than that in earlier trials.
The use of dexamethasone in our trial was limited to a single
administration on day 1. Oral dexamethasone is recommended for
the prevention of delayed emesis following HEC and MEC [2,3],
but recently there has been clinical interest in reducing the use
of steroids [28–31].
Our trial assessed for the ﬁrst time efﬁcacy of antiemetic therapy
in the setting of ABVD regimen in patients with Hodgkin Lym-
phoma. Overall, a single dose of palonosetron plus a single dose of
dexamethasone effectively controlled CINV during an entire cycle
of ABVD, avoiding CINV of the grade 3 and 4.
The antiemetic activity of palonosetron might possibly be
improved by combination with NK-1 receptor antagonists; this is
of interest as a further strategy of future investigation and is in
accordance with antiemetic guidelines [2,3].
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